24 completed, 14 terminated, 6 recruiting, 4 withdrawn. 32 Phase 2, 19 Phase 1, 5 Phase 3, 1 Phase 4.
Follow capmatinib: new trials by email Literature Review of capmatinib trials Research Report on capmatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations Capmatinib - Solid Tumour, Haematological Malignancy | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2024-11-19 | 2025-11-24 |
| Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations Dabrafenib + Trametinib, Capmatinib - NSCLC, BRAF V600 Mutation | Phase 2 | Not yet recruiting | Sun Yat-sen University | 40 | 2024-02-01 | 2023-10-10 |
| Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations Capmatinib - Non-small Cell Lung Cancer | Phase 2 | Withdrawn | Timothy Burns, MD, PHD | 2023-10-03 | 2024-06-17 | |
| A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea Capmatinib - Non-Small-Cell Lung Carcinoma | Recruiting | Novartis Pharmaceuticals | 44 | 2023-06-12 | 2026-06-01 | |
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) Biospecimen Collection, Capmatinib, Computed Tomography - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Recruiting | SWOG Cancer Research Network | 66 | 2023-05-05 | 2026-06-03 |
| DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol Alectinib, Atezolizumab, Entrectinib - Haematological Malignancy, Solid Tumour | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 825 | 2023-03-01 | 2026-07-01 |
| A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer Capmatinib, Amivantamab - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 57 | 2022-12-13 | 2026-09-25 |
| Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. Capmatinib 150 mg, Capmatinib 200 mg - Non-Small Cell Lung Carcinoma | Phase 4 | Completed | Novartis Pharmaceuticals | 50 | 2022-09-03 | 2026-10-26 |
| Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test Neratinib, Capmatinib - Metastatic Breast Cancer, Breast Cancer | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 10 | 2022-08-18 | 2025-06-11 |
| Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation Capmatinib, Trametinib - Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer | Phase 1 | Terminated | Collin Blakely | 3 | 2022-08-10 | 2024-06-11 |
| Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC capmatinib - Non-small Cell Lung Cancer | Phase 2 | Terminated | Novartis Pharmaceuticals | 4 | 2022-08-10 | 2025-10-16 |
| Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma Capmatinib, Spartalizumab - Oesophageal Adenocarcinoma, Gastric Adenocarcinoma | Phase 2 | Suspended | Assistance Publique - Hôpitaux de Paris | 90 | 2022-03-22 | 2023-02-03 |
| RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU) Capmatinib - MET Alterations, Non Small Cell Lung Cancer | Completed | Intergroupe Francophone de Cancerologie Thoracique | 182 | 2021-11-29 | 2023-01-06 | |
| Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib Capmatinib - Metastatic Non-Small Cell Lung Cancer | Completed | Novartis Pharmaceuticals | 68 | 2021-10-01 | 2023-01-09 | |
| Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy Capmatinib, Osimertinib, Pemetrexed - Carcinoma, Non-Small-Cell Lung | Phase 3 | Terminated | Novartis Pharmaceuticals | 6 | 2021-09-22 | 2024-03-05 |
| Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation Capmatinib - Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Completed | Novartis Pharmaceuticals | 36 | 2021-05-17 | 2026-03-31 |
| A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases Capmatinib - Non-small Cell Lung Carcinoma (NSCLC) | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2020-11-11 | 2020-12-03 | |
| Special Drug Use-results Surveillance of Tabrecta Tablets Tabrecta tablets - Non-small Cell Lung Cancer | Completed | Novartis Pharmaceuticals | 109 | 2020-11-02 | 2025-09-15 | |
| Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation Capmatinib, Docetaxel - Carcinoma, Non-Small-Cell Lung | Phase 3 | Terminated | Novartis Pharmaceuticals | 22 | 2020-09-25 | 2025-05-16 |
| Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations Spartalizumab, Capmatinib, spartalizumab placebo - Carcinoma, Non-Small-Cell Lung | Phase 2 | Terminated | Novartis Pharmaceuticals | 31 | 2020-08-19 | 2024-10-09 |
Showing 20 of 55. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (26) · Lung Neoplasms (10) · Adenocarcinoma of Lung (7) · Neoplasms (6) · Neoplasm Metastasis (5) · Carcinoma (3) · Glioblastoma (3) · Melanoma (3) · Colorectal Neoplasms (2) · Gliosarcoma (2) · Hematologic Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Sarcoma (2) · Adenocarcinoma Of Esophagus (1)
Novartis Pharmaceuticals (34) · Cancer Research UK (2) · Asan Medical Center (1) · Assistance Publique - Hôpitaux de Paris (1) · Collin Blakely (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Incyte Corporation (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Intergroupe Francophone de Cancerologie Thoracique (1) · Janssen Research & Development, LLC (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · National Cancer Institute (NCI) (1) · Pfizer (1) · SCRI Development Innovations, LLC (1)
United States (29) · Spain (21) · France (20) · Germany (19) · Italy (19) · South Korea (12) · Canada (11) · Netherlands (11) · Singapore (10) · United Kingdom (10) · Australia (9) · Belgium (9) · China (9) · Japan (9) · Hong Kong (7)
Matthew Krebs, Dr (2) · Adil Daud (1) · Antoine Italiano (1) · Birgit Geoerger, MD (1) · Collin M Blakely, MD, PhD (1) · Karen Kelly (1) · Kent C. Shih, M.D. (1) · Lance Leopold (1) · Rachel Layman (1) · Ramaprasad Srinivasan, M.D. (1) · Rebecca S. Heist, MD (1)
PMID 26825170, PMID 30156984, PMID 31538815, PMID 31776899, PMID 31778267, PMID 31853265, PMID 32240796, PMID 32410080, PMID 32713836, PMID 32877583, PMID 33892407, PMID 34046915, PMID 34053700, PMID 34347542, PMID 34376578, PMID 34543871, PMID 34740331, PMID 35292802, PMID 36822130, PMID 38617599, PMID 38763104, PMID 38986421, PMID 39362249, PMID 41838385, PMID 41914670, PMID 42686334
2014 (4), 2018 (3), 2016 (2), 2019 (2), 2015 (1), 2017 (1), 2023 (1), P30CA093373 (1), U10CA180888 (1)